Background. Protein carbamylation is one of the nonenzymatic reactions involved in protein molecular ageing. We sought to investigate the relationship between urea levels and protein carbamylation, and whether a Mediterranean diet (MD) and a very low protein diet (VLPD) reduce protein carbamylation through reduction in urea levels in patients with chronic kidney disease (CKD). Methods. This is a prospective, randomized, crossover controlled trial that investigated 60 patients with CKD grades 3B-4 (46 males, mean age of 67 years). The enrolled CKD patients were randomly assigned (1:1) to two different nutritional treatment arms: (i) 3 months of free diet (FD), 6 months of VLPD, 3 months of FD and 6 months of MD; and (ii) 3 months of FD, 6 months of MD, 3 months of FD and 6 months of VLPD. Blood levels of lysine (Lys) and homocitrulline (Hcit) and their ratio were used as markers of cyanate levels. Due to a lack of pre-existing data on the potential effects of different dietary regimens and in light of the exploratory nature of the study, no formal sample size estimation was carried out. Results. At study completion, lower diastolic blood pressure and decreased serum levels of urea, sodium, phosphorus and parathyroid hormone, but higher serum levels of bicarbonate and haemoglobin, were noted with MD and VLPD. When compared with FD, both MD and VLPD were also associated with a decrease in serum Hcit levels and Hcit/Lys ratios (P < 0.001). Notably, reductions in urea levels correlated with substantial reductions in Hcit levels (R 2 ¼ 0.16 and 0.17 for VLPD and MD, respectively). Conclusion. In conclusion, nutritional treatments that significantly decrease serum levels of urea are associated with reduced protein carbamylation.
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I N T R O D U C T I O N
Chronic kidney disease (CKD) is a syndrome characterized by high cardiovascular (CV) mortality, which is not fully explained by the traditional risk factors for CV disease such as the Framingham risk factors [1] . CKD plausibly triggers metabolic pathways involved in micro-inflammation [2, 3] and atherosclerosis [4] . It also causes accumulation of uraemic toxins that may play an important role in vascular dysfunction and accelerated atherosclerosis [5] [6] [7] . However, the role of many of these toxins is yet to be clarified.
Traditionally, urea has not been associated with a pathogenetic role in CKD, whereas it has been related to minor clinical events such as uraemic fetor. Indeed, urea is mainly perceived as a marker of metabolic imbalance or dialysis efficacy (Kt/V) [8] . However, a small amount of urea (<1%) spontaneously dissociates into ammonium ions and cyanate [9] . In turn, cyanate triggers protein carbamylation [10] , a chemical reaction that involves covalent binding of cyanate to the functional groups of many amino acids [11, 12] . For example, lysine (Lys) carbamylation leads to the production of homocitrulline (Hcit), a compound that is commonly used as a marker of the overall carbamylation processes [12] .
Protein carbamylation is one of the non-enzymatic reactions involved in protein molecular ageing (i.e. glycation, oxidation, etc.); the products derived from these reactions are called 'posttranslational modification-derived products' [13] . Although different pathways may lead to cyanate production and carbamylation [14] , it is commonly accepted that post-translational modification-derived products are involved in inflammation, atherosclerosis [15] and fibrosis, which may accelerate the progression of renal failure [16] .
Recently, the beneficial effects of a Mediterranean diet (MD) and a very low protein diet (VLPD) with keto-analogues have become apparent [17] [18] [19] [20] [21] [22] [23] . Some investigators have demonstrated the ability of MD to positively influence gut microbiota, reduce microbial-derived uraemic toxins and improve endothelial function [18] [19] [20] . On the other hand, VLPD has been shown to be effective in reducing blood urea concentration, as demonstrated also by our group [21] [22] [23] . Of interest, VLPD is composed of protein-free food, vegetables and a mixture of essential amino acids (EAAs) and keto-analogues of nonessential amino acids (NEAAs). Keto-analogues acquire the amino group from urea, leading to both EAA formation and urea consumption [24] .
The purpose of this study was to verify the hypothesis that the carbamylation process is enhanced in patients with higher urea levels and that MD and VLPD are able to reduce carbamylation through decreased urea levels in patients with moderate CKD.
M A T E R I A L S A N D M E T H O D S
This is a prospective, randomized, crossover controlled trial. It was carried out according to the Declaration of Helsinki (IV Adaptation) and approved by the local Ethics Committee (Campania Nord Ethics Committee, Avellino, Italy). Written consent was obtained from all subjects. The study protocol was registered on ClinicalTrials.gov, identifier number NCT02302287.
One of the primary endpoints of the study was to test the impact of different nutritional regimens on gut microbiota by detecting variations in indoxyl sulfate and p-cresol levels. Results related to this primary endpoint will be reported in a subsequent manuscript, since characterization of the intestinal microbiota is yet to be carried out. Here, we report results regarding another primary endpoint, which is the impact of different nutritional regimens on urea levels and protein carbamylation.
We recruited incident patients referred to a tertiary nephrology clinic, with the following inclusion criteria: (i) age >18 years; (ii) CKD stages 3B-4 [estimated glomerular filtration rate (eGFR) between 15 and 45 mL/min/1.73 m 2 , glomerular filtration rate calculated with creatinine-EPI]; (iii) adherence to prescribed therapies; and (iv) ability to provide a signed informed consent. The exclusion criteria were: (i) change in the eGFR by >30% within the last 3 months; (ii) acute intercurrent illness during the previous 3 months; (iii) severe undernutrition, as indicated by a body mass index (BMI) of <20 kg/m 2 and serum albumin <3.2 g/dL, or BMI <17.5 kg/m 2 independent of albumin values, or a body weight reduction of >5% within the last month or >10% within the last 6 months; (iv) pregnancy or breastfeeding; (v) chronic treatment with steroids or cytotoxic drugs; (vi) fast progressing glomerulonephritis; (vii) active systemic lupus erythematosus (SLE) and vasculitis; (viii) gastrointestinal diseases (Crohn's disease, ulcerative colitis, coeliac sprue, stypsis); (ix) infectious diseases; (x) cardiac failure New York Heart Association (NYHA) stages III-IV; (xi) advanced liver cirrhosis; (xii) active cancer; (xiii) severe encephalopathy associated with lack of spontaneous feeding; (xiv) chronic obstructive respiratory diseases that need oxygen treatment; (xv) use of antibiotics or probiotics until 15 days before study enrolment; and (xvi) psychiatric illness or inability to assess at follow-up.
Sixty CKD patients fulfilling the inclusion criteria were divided into two treatment arms, with a 1:1 ratio, by software randomization: The main difference between the MD and VLPD regimens is the presence of animal proteins in the MD regimen and the inclusion of keto-analogues of NEAAs in the VLPD regimen. The exact composition of VLPD tablets were described in our previous work [22] . A washout period of 3 months with FD between the MD and VLPD regimens was deemed necessary to avoid any potential carry-over effect of MD or VLPD.
Adherence to a prescribed diet was evaluated using dietetic interviews completed by patients during an entire week every 2 months. In detail, protein intake was estimated with the Maroni formula [25] using 24-h urine collections, which patients and their relatives were extensively trained on how to perform correctly.
Patients underwent clinical examinations and provided blood, urine and faecal samples at the beginning of the study (T0), then after 3 (T3), 9 (T9), 12 (T12) and 18 (T18) months. Cyanate level variations were indirectly estimated by measuring Lys and Hcit levels and evaluating their blood concentration ratios; Hcit results from cyanate and Lys interaction [12] .
To perform Lys and Hcit analyses, 50 lL of serum samples were acid-hydrolysed with 1 mL of 6 N hydrochloric acid (HCl) in vacuum-sealed hydrolysis vials at 110 C for 22 h. The vials were cooled after hydrolysis and samples underwent complete lyophilization. Residues were then dissolved in a suitable volume of 0.1% formic acid (v:v) and centrifuged at 5000 g at 4 C for 5 min. Each resulting sample was analysed by an LC/MS/ MS apparatus, comprising an Agilent 1100 HPLC system (Agilent, Santa Clara, California, USA) coupled with an API3000 mass spectrometer (AB Sciex, Milano, Italy) equipped with an electrospray ion source and a triple quadrupole mass analyser. Chromatographic separation of amino acids was performed on a Luna C18 column (2.1 Â 150 mm, 3.5 lm particle size) (Phenomenex, Torrance, California, USA), using 20% acetonitrile in 0.1% formic acid as elution solution. The mass spectrometer was operated in the positive ion, multiple reaction monitoring mode, to monitor the transitions 147 ! 84 and 190 ! 127 and detect and quantify Lys and Hcit, respectively. LC/ MS/MS results were analysed using the Analyst software (AB Sciex).
STATISTICAL ANALYSIS
Due to a lack of pre-existing data on the potential effects of different dietary regimens and in light of the exploratory nature of the study, no formal sample size estimation was carried out. Data were presented as the mean 6 standard deviation (SD), median (interquartile range) or count (percentage) when appropriate. Differences between dietary regimens were tested using parametric (Student's t-test) or non-parametric (Wilcoxon rank sum test) tests for normally and non-normally distributed variables, respectively.
To gauge the relative contribution of changes in urea levels to changes in Hcit levels (a biomarker of protein carbamylation) [12] , linear regression analysis was performed. The percentage change in both serum urea and serum Hcit levels was calculated as: [(value with FD À value at the end of each nutritional intervention)/value with FD] Â 100. A positive value suggested a decrease from baseline. It was noted that a significant nonlinear component of the association between changes in serum urea levels and serum Hcit levels was apparent in both nutritional interventions. Thus, all models were adjusted for serum urea levels at baseline, as well as for the interaction of serum urea levels at baseline and changes in serum urea levels at the end of each nutritional intervention. Due to the exploratory nature of these analyses and taking into account that each patient is both case and control at the same time, no further statistical adjustment was performed.
All analyses were conducted as intention to treat. Two-tailed probability values of 0.05 were considered statistically significant. Analyses were completed using R version 3.1.3 (2015-03-09) (The R Foundation for Statistical Computing, Vienna, Austria). Table 1 shows anthropometrical, clinical and biochemical data of included patients (n ¼ 60, 46 males, mean age 66 years) enrolled in the study.
R E S U L T S
All enrolled patients underwent routine blood examinations every 3 months for residual renal function measurements. None of the patients needed treatment with antibiotics in the first 3 months on the FD regimen at the beginning of the study. However, during follow-up, nine patients were treated with antibiotics. Five patients were prescribed quinolones for 1 week for urinary infections (one patient was given the antibiotic after 1 month on the VLPD regimen, and two after 2 months and another two after 3 months on the MD regimen). The remaining four patients were prescribed quinolones and ampicillin for pneumonia. All patients interrupted their involvement in the study during their infective illness and subsequently resumed their participation after a 3-month washout period, during which they were first placed on the FD regimen, followed by the other dietary regimens as planned in the study protocol.
All patients completed the study. Five patients were initiated on dialysis treatment (four had haemodialysis and one peritoneal dialysis) during the last 6 months of the study (three patients from group A on the MD regimen, two from group B on the VLPD regimen). Of these five patients, two started dialysis during their third month on the MD and VLPD regimens, respectively, two during their fourth month on the MD regimen, and one during their fifth month on the MD regimen. Blood samples to measure Hcit levels in these patients were collected before dialysis treatment was initiated.
Our data suggested that VLPD was more effective than FD and MD in lowering the systolic (P < 0.001) and diastolic (P ¼ 0.47) blood pressure (P ¼ 0.047) and levels of serum urea (P ¼ 0.001), sodium (P < 0.0019), phosphorus (P < 0.0019), parathyroid hormone (P < 0.0019) and homocysteine (P < 0.0019). Moreover, VLPD was associated with increased serum bicarbonate and haemoglobin levels (P < 0.001) ( Table 1 ). In particular, in comparison with FD, MD and VLPD induced a urea level reduction of 22% and 64%, respectively, whereas VLPD resulted in a urea level reduction of 54%, compared with MD. This is explained by a reduced protein intake obtained with VLPD (0.48 6 0.14 g/kg bw/day), compared with that obtained with MD (0.9 6 0.2 g/kg bw/day) and FD (1.21 6 0.23 g/kg bw/ day). Moreover, the body weight of patients did not change significantly, showing correct energy intake as recommended for CKD (30-35 kcal/kg bw/day).
Regarding urinary elements and metabolites, results showed that MD and VLPD lowered sodium and potassium levels, but only VLPD lowered chloride (P ¼ 0.001) and urinary urea nitrogen levels (P ¼ 0.001), and the fractional excretion of phosphorus (P ¼ 0.001) and protein/creatinine ratio (P ¼ 0.001) ( Table 1) . Table 2 shows serum Hcit levels and Hcit/Lys ratios, representing the markers of protein carbamylation, for each nutritional regimen. MD lowered Hcit levels by 27.6% (P < 0.001) and Hcit/Lys ratios by a non-significant 10.5% (P ¼ 0.77), compared with FD. VLPD lowered Hcit levels by 41.4% and Hcit/ Lys ratios by 28.9%, compared with FD (for both comparisons, P < 0.001). Moreover, VLPD lowered Hcit levels by 19.0% (P < 0.001) and Hcit/Lys ratios by 20.6%, compared with MD (P < 0.001). Figures 1 and 2 show the bivariate relationship between serum urea levels and markers of carbamylation (Hcit levels and Hcit/Lys ratio) according to the different nutritional regimens, namely FD, MD and VLPD. The median value of serum Hcit levels was 16.2 nM (min-max: 8.3-20.5) with FD, 10.9 nM (min-max: 6.9-14.7) with MD and 9.0 nM (min-max: 5.8-12.0) with VLPD. A similar reduction trend was observed for serum urea levels, with a median value of urea levels with FD of 174.5 mg/dL (min-max: 101-225), 146.3 mg/dL (min-max: 60-187) with MD and 67 mg/dL (29-120) with VLPD [20% and 67% reduction (P < 0.001) for MD and VLPD, respectively] ( Table 2) . As demonstrated in Figures 1 and 2 , Hcit and protein carbamylation levels were significantly correlated with serum urea levels (R 2 ¼ 0.5; P < 0.0001). To further explore the association between serum urea and Hcit levels and protein carbamylation, as well as the influence of MD and VLPD on them, the relative changes of serum urea and serum Hcit levels according to the different nutritional regimens were plotted (Figures 3 and 4) . Although a greater reduction in serum urea levels with a large reduction in Hcit levels was expected with both MD and VLDP, it was apparent that the association between changes in serum urea and Hcit levels was not linear with either nutritional regimen. Tables 3 show  results of the regression analysis performed to assess the bivariate association of the percentage changes in serum urea and Hcit levels with both MD and VLPD. The relative changes in Hcit levels were associated with relative changes in serum urea levels (significant P-value for b-coefficient for both MD and VLPD). However, changes in Hcit levels also depended on the absolute values of serum urea levels before initiation of MD and Na, sodium; K, potassium; PTH, parathyroid hormone; Hb, haemoglobin; CRP, C-reactive protein; Na-u, urinary sodium, K-u, urinari potassium, UUN, urinary urea; Creatinine-u, urinary creatinine; FeNa, fractional urinary excretion of sodium; FeP, fractional urinary excretion of phosphate; Pr/Cr ratio, protein/creatinine ratio. *Bonferroni test: P < 0.05 versus FD and MD. **Bonferroni test: P < 0.05 versus FD.
VLPD, suggesting a non-linear component of the bivariate association of serum urea and Hcit levels with both MD and VLPD. The regression model explains only $16-18% of the variations in Hcit level reduction (R 2 ¼ 0.178 and 0.163 for percentage changes in Hcit levels with MD and VLPD, respectively). Taken together, these results suggest that factors other than urea are also important determinants of Hcit level changes and the absolute value of urea levels may affect and/or modulate carbamylation and, as a consequence, may contribute to cyanate production.
Patients continued their pharmacological therapy (including anti-hypertensive drugs, phosphate binders, erythropoietin, vitamin D and others) that was initiated before commencement of the study, with doses adjusted according to their clinical conditions. Among 28 patients who were taking phosphate binders while on the FD and MD regimens, 12 either reduced the doses or interrupted phosphate binders. Of the 57 patients on antihypertensives, 16 reduced the drug doses while on the VLPD regimen. Finally, seven of the 36 subjects on erythropoietin treatment reduced the drug doses while on the VLPD regimen.
D I S C U S S I O N
CKD is associated with a high CV mortality rate, and a 30-year-old CKD patient usually presents with a biological age comparable to that of a 70-year-old healthy man [1] . Early ageing of the CKD population seems to be related to early atherosclerosis and micro-inflammation [1] [2] [3] 7] . Uraemic toxins might play an important role in the development of atherosclerosis and micro-inflammation in these patients. Intriguingly, protein carbamylation and cyanate compounds could represent one of the potential links between CKD and CV diseases. Indeed, protein carbamylation and cyanate have been implicated in many pathophysiological events in renal failure, for example in the 'uraemic state' process [26] [27] [28] . Protein carbamylation produces structural and functional changes to proteins themselves via two pathways that lead to isocyanic acid generation. The first pathway is through spontaneous decomposition of urea into ammonium ions (NH4 þ ) that interact with cyanate. The second pathway depends on myeloperoxidase action and thiocyanate oxidation [13, 15, 29, 30] . The first pathway is a unphysiological process that is amplified and strictly correlated with high levels of urea, as occurs in CKD, but there are also other factors that contribute to this process [13, 15, 29] . The non-enzymatic reaction of the amine and sulfur-containing groups with the e-amine group of Lys produces post-translational changes with the formation of Hcit [31] . This latter compound represents a direct measure of protein carbamylation [32] and an independent CV and mortality risk factor [33] [34] [35] [36] .
In a study of 347 haemodialysis patients, Koeth and colleagues [33] showed that Hcit levels significantly predicted CV risk [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.5-3.9; HR 2.3, 95% CI 1.5-3.7, highest tertile versus middle and lower tertiles, respectively]. The authors also showed a significant correlation between Hcit and urea levels and estimated that about 14% of Hcit level variations were dependent on urea levels [33] . These recent data confirmed an earlier report by Wang et al. [15] that also provided evidence of a prominent urea-independent pathway in CKD through thiocyanate, with intermediates of myeloperoxidase and hydrogen peroxide (H 2 O 2 ). Therefore, not only do Hcit levels measure cyanate-dependent carbamylation, but they also measure cyanate-independent carbamylation. For this reason, Hcit cannot be considered as an index of cyanate generation [15] . Our data also confirmed that Hcit level variations are 20% dependent on urea level reductions. Therefore, nutritional therapy may be used to reduce urea levels, and hence protein carbamylation. Urea lowering to reduce protein carbamylation in CKD Carbamylation leading to protein alterations is irreversible. Protein synthesis is a continuous physiological process; carbamylation of newly synthesized proteins may be reduced in the presence of improved metabolic conditions in the organism. Although there are no consistent data in the literature and given the effects of carbamylation and cyanate production on atherosclerosis, insulin resistance and inflammation [15] , it is possible to hypothesize that carbamyl compounds would lead us to modify our current concept of ageing and CKD [37, 38] .
Even if urea has traditionally been associated so far with fewer clinical events, it may trigger protein carbamylation and cyanate urea-dependent production [39] [40] [41] . Furthermore, protein carbamylation and cyanate production suggest an association with insulin resistance [40] . Systemic inflammation and chronic exposure to high serum urea levels cause a breakdown of the intestinal cellular junction and modify microbial flora [42, 43] in CKD, resulting in an increased absorption of uraemic toxins as indoxyl sulfate and p-cresol sulfate. These observations have rekindled research interest in urea [39, 44] .
Urea has been neglected as a uraemic toxin until recently. In 1972, experimental studies on dialysis showed evidence that addition of urea to the dialysis bath produced only moderate symptoms such as headache and sleepiness [45] . Recently, some studies showed that increased urea levels resulted in relevant toxic effects [39, 44] . In fact, nowadays the idea of the direct toxicity of urea is acknowledged, with CV (endothelial dysfunction, atherosclerosis, vascular smooth muscle cell apoptosis), inflammatory (altered microbioma, epithelial barrier breakdown), renal (such as fibrosis), endocrine (adipocyte dysfunction, insulin resistance) and haematological (anaemia) consequences [37] [38] [39] [40] .
The only way to reduce urea levels in CKD patients is by nutritional therapy with a low protein content and high biological value, and an adequate energy intake [24] . Obviously, MD, namely a diet with 0.8-1 g/kg bw/day of protein content that is poor in red meat, may also contribute to reducing urea levels in a CKD patient, compared with a diet with a higher protein content.
On the other hand, VLPD is a nutritional therapy based on a vegetarian diet with the addition of AAEES and keto-analogues that helps to: (i) lower the sodium intake, achieve better blood pressure control [22] and reduce erythropoietin dosage [21] ; (ii) decrease proteinuria [23] ; (iii) lower serum phosphorus and fibroblast growth factor-23 levels [46] ; and (iv) decrease circulating levels of indoxyl sulfate [47] . Results from the present study confirm our previous findings, demonstrating that VLPD is very effective in lowering serum urea levels [21] [22] [23] , possibly through reutilization of the urea amino group to synthesize NEAAs [24] . Moreover, we noted that, during VLPD administration, blood urea levels decreased by 64% compared with FD, and by 54% compared with MD, and 28% of patients who were on VLPD achieved complete normalization of serum urea levels. Current results also corroborate the positive effects of VLPD on sodium intake, hypertension, phosphorus intake, proteinuria, metabolic acidosis, insulin resistance and anaemia [21-23, 46, 47] . Notably, despite being based on vegetal nutrients, VLPD was not found to be associated with a risk for hyperkalaemia, since it improves metabolic acidosis in CKD by providing bicarbonate ions contained in vegetal foods [48] . Moreover, there is a poorly understood link between urea levels and insulin secretion [49] and correction of metabolic acidosis in CKD [50] .
In addition, we can add to previous observations that protein carbamylation follows a reduction trend similar to that observed for serum urea levels. In our study, there was a statistically significant decrease in protein carbamylation with VLPD, compared to with MD and FD (Figures 3 and 4) , despite a limited intervention period of 6 months, considering that carbamylated proteins usually have a longer half-life. For instance, the half-life of the glycated form of carbamylated haemoglobin has been shown to be up to 6 months [51] . Theoretically, some of the positive aspects of VLPD could be attributed to lower levels of protein carbamylation. For example, it has been shown that the carbamylated form of erythropoietin is less effective in stimulating the bone marrow and that erythropoietin resistance is higher in haemodialysis patients with higher levels of protein carbamylation [51, 52] .
Demonstrating protein carbamylation reduction with MD and VLPD is crucial. In fact, protein carbamylation has been associated with inducing atherosclerosis via many damage pathways, such as the pathway involving carbamylated lowdensity lipoproteins (LDLs). Carbamylated LDLs present with a reduced affinity for their receptor and lower plasma clearance, resulting in macrophage scavenger recognition and foam cell induction [16, 27, 28] . Furthermore, Shaykh and collaborators [16] found that carbamylated fetal bovine serum proteins accelerated the growth of mesangial cells, increased the accumulation of collagens I and IV, without a concomitant increase in protein synthesis in general, thus activating mesangial cells to a profibrogenic phenotype.
Finally, Vanholder et al. [53] recently confirmed that urea is an important source of carbamylated compounds that trigger profibrotic damage to mesangial cells, with concurrent structural changes in collagen, vascular damage and endothelial cell apoptosis, promoting atherosclerosis.
The main limitations of this study are the relatively small sample size and lack of investigation of the clinical effects, such as atherosclerosis, and cyanate and carbamylation level reduction. On the other hand, the rigorous study design (crossover) Table 3 . Regression analysis to investigate the bivariate association of relative changes (percent change) of serum urea and serum Hcyt (marker of protein carbamylation -dependent variable in the regression models) during Mediterranean (MD) diet and very low protein diet with Ketoanalogues (VLDP). All models are adjusted for serum urea before the nutritional intervention (free diet) and for the interaction of serum urea before the nutritional intervention (free diet) and the precent reduction of urea during the nutritional intervention Urea lowering to reduce protein carbamylation in CKD enabled a robust demonstration of reduction of cyanate and carbamylation levels associated with a decrease in urea levels, achieved with different nutritional regimens. As previously shown by others, it is possible that MD [17] [18] [19] [20] and VLPD [54] [55] [56] could improve survival rates in CKD patients and exert anti-atherosclerotic effects through urea-carbamylation control. This hypothesis, however, is beyond the scope of this study and needs to be investigated in future specifically designed randomized controlled trials. To our knowledge, the present study demonstrates for the first time that nutritional therapy that induces decreased urea levels can reduce protein carbamylation as well as cyanate production. Based on the expanding body of evidence and current findings, and given the importance of phosphorus, hypertension, metabolic acidosis, anaemia and others as well-recognized treatment targets, it seems reasonable and achievable to consider control of serum urea levels as a therapeutic target in CKD [30] . However, the clinical impact of MD and VLPD on carbamylation and other hard outcomes warrants further investigation. 
